Evidence mapPaperPMID 40660190Full record

ArticleBMC biology2025

NeXtMD: a new generation of machine learning and deep learning stacked hybrid framework for accurate identification of anti-inflammatory peptides.

Chengzhi Xie, Yijie Wei, Xinwei Luo, Huan Yang, Hongyan Lai, Fuying Dao, Juan Feng, Hao Lv

Abstract read
In one paragraph

Article in BMC biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chengzhi XieThe Clinical Hospital of Chengdu Brain Science Institute, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 610054, China.
Yijie WeiThe Clinical Hospital of Chengdu Brain Science Institute, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 610054, China.
Xinwei LuoThe Clinical Hospital of Chengdu Brain Science Institute, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 610054, China.
Huan YangYangtze Delta Region Institute (Quzhou), University of Electronic Science and Technology of China, Quzhou, Zhejiang, 324000, China.
Hongyan LaiChongqing Key Laboratory of Big Data for Bio Intelligence, Chongqing University of Posts and Telecommunications, Chongqing, 400065, China.
Fuying DaoSchool of Biological Sciences, Nanyang Technological University, Singapore, 639798, Singapore. fuying.dao@ntu.sg.edu.
Juan FengThe Clinical Hospital of Chengdu Brain Science Institute, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 610054, China. fengjuan@uestc.edu.cn.
Hao LvThe Clinical Hospital of Chengdu Brain Science Institute, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 610054, China. hao.lyu@uestc.edu.cn.

Funding

China Postdoctoral Science Foundation 2023TQ0047National Natural Scientific Foundation of China 62402089Sichuan Science and Technology Program 2025ZNSFSC1465Undergraduate Elite Experience Program of University of Electronic Science and Technology of China 2024GFTY018
6 · The paper itself

Abstract

backgroundAccurate identification of anti-inflammatory peptides (AIPs) is crucial for drug development and inflammatory disease treatment. However, the short length and limited informational content of peptide sequences make precise computational recognition particularly challenging. While various machine learning and deep learning approaches have been explored, their limitations in feature representation and model integration hinder the effective discovery of novel AIPs.

resultsIn this study, we present NeXtMD, a novel dual-module stacked framework that integrates both machine learning (ML) and deep learning (DL) components for accurate AIP identification. NeXtMD systematically extracts four functionally relevant sequence-derived descriptors-residue composition, inter-residue correlation, physicochemical properties, and sequence patterns-and utilizes a two-stage prediction strategy. The first stage generates preliminary predictions using four distinct encoding strategies and ML classifiers, while the second stage employs a multi-branch residual network (ResNeXt) to refine prediction outputs. Benchmark evaluations demonstrate that NeXtMD outperforms current state-of-the-art methods on multiple performance metrics. Moreover, NeXtMD maintains strong generalization capabilities when applied to unseen peptide sequences, showing its robustness and scalability.

conclusionsNeXtMD offers a high-performance and interpretable computational framework for AIP identification, with significant potential to facilitate the discovery and design of peptide-based anti-inflammatory therapeutics. The architecture and methodological innovations of NeXtMD also provide a generalizable strategy that can be adapted to other bioactive peptide prediction tasks, supporting broader applications in therapeutic peptide development.

Indexed as

Anti-Inflammatory AgentsDeep LearningMachine LearningPeptidesAnti-Inflammatory AgentsPeptidesAnti-inflammatory peptideBioinformaticsDeep learningMachine learning

Identifiers

PMID40660190
PMCPMC12261603

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.